Why the Hexo (TSX:HEXO) Stock Price Fell 19.8% in January

Hexo Corp.’s (TSX:HEXO)(NYSE:HEXO) stock price heads lower on news of more shareholder dilution and continued financial difficulties.

| More on:
A stock price graph showing declines

Image source: Getty Images.

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Cannabis stocks like Hexo (TSX:HEXO)(NYSE:HEXO) had their heads handed to them in January once again, as the downward spiral continues. When a bubble bursts, it falls hard, and Hexo’s stock price is a prime example of this. Down 19.8% in January, 75.6% in the last year and 85.1% from its highs, Hexo stock still carries too much risk and uncertainty for investors, as the momentum is clearly negative.

So, why did Hexo’s stock price fall again in January, and what, if anything, should investors do at this point?

Troubles in the cannabis industry send Hexo’s stock price cratering

The cannabis industry continues to be fraught with difficulties, including pricing pressure, a slow roll-out of retail stores, and a general uncertainty regarding regulation. These problems have impacted all of the cannabis stocks, and Hexo was just another one caught up in this mess.

After a period of high-flying stock returns, the day of reckoning has come. Highly dilutive acquisitions, share issues, and a general lack of attention to shareholder and financial returns have resulted in many of the problems at Hexo today. And the dilution continues, as Hexo attempts to recover from recent financial disappointments and difficulties. In January, the company raised another $20 million at US$1.67 per share.

Newstrike acquisition troubles tank Hexo’s stock price

Hexo’s 2019 acquisition of Newstrike, which seemed reasonable at the time in terms of strategic direction at least, has now come to light as a big blunder on the part of Hexo management.

There were plenty of disappointments, but the biggest one was the revelation that Newstrike was growing product illegally at its Beamsville facility in Niagara. Hexo immediately stopped production in that illegal area, and that greenhouse is no longer being used. But the stain on Hexo remains.

Hexo’s stock price heads to zero on bankruptcy concerns

Unpaid bills related to Hexo’s Newstrike acquisition has prompted MediPharm to sue Hexo for $9.8 million, the company has reported greater-than-expected losses over the last few quarters and has burned through almost $80 million in the last quarter alone. With a dwindling cash balance that now stands at $54.6 million, we can see the precarious situation that Hexo is in.

On the plus side, Hexo still has its joint venture with Molson. This joint venture is Hexo’s unique opportunity to offer non-alcoholic, cannabis-infused beverages. It is a promising growth area in the cannabis edibles market.

Foolish final thoughts

With a product offering including pre-rolls, flower, oil, and premium products, the company is still working hard toward its goal of becoming the premier-branded cannabis company in the edibles space.

That problem is that in the cannabis sector, we are clearly at the beginning stages, and as such, we can expect that many of the cannabis producers today will not be around in the coming years. There is great uncertainty and risk associated with this sector. Investors who wish to gain exposure to the potential upside may want to consider owning a basket of cannabis stocks to diversify company-specific risks.

In closing, I would like to remind Foolish investors of our belief in holding great businesses for the long term. While this belief remains intact, we are also aware that sometimes, short-term stock price movements create opportunities to create wealth. By blending this long-term focus with a keen eye for short-term stock mispricings, we can use both strategies in harmony, and our quest for financial freedom can be fulfilled.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Karen Thomas has no position in any of the stocks mentioned. The Motley Fool recommends HEXO. and HEXO.

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »